30.04.2012 - The acquisition of Genzyme shows its benefits: Sanofi reported strong
sales and earnings growth in the first quarter of 2012.
Paris – The French drug maker reported a net profit of €1.8bn, up from €1.2bn in the first quarter of 2011. The better earnings, however, were not enough to change the company's gloomy outlook for the coming year. The executives warned that earnings in the rest of the year would be hit by the loss of US market exclusivity of its blood thinner Plavix (clopidogrel) in May, and blood pressure drug Avapro (irbesartan) at the end of March. Net sales rose more than 9% to €8.5bn, with revenue at the flagship pharmaceutical division, increasing 8.8% at constant exchange rates, to €7.32bn.
Genzyme contributed €841m. Sanofi benefited from growth in emerging markets (+9.9% to €2.6bn), with Brazil, Russia, Indian and China together contributing €917m. Sanofi's diabetes franchise also increased by 14.4% to €1.3bn. The contribution of Lantus (insulin glargine) is €1.1bn (+17.2%), which means it is the company's top-selling drug. Sanofi's oncology business grew by 12.8% to €741m, with Eloxatin (oxaliplatin) generating €321m in the US.
Sanofi's CEO Chris Viehbacher emphasised that the patent loss of former key products like Plavix and Avapro had been something the French multinational had long foreseen. According to Viehbacher, the company is now entering the final phase of its patent cliff. He said that Sanofi had built six "growth platforms" to replace sales lost to generic competition and generate sustainable growth. He noted that these new products would not be dependent on patents to the same extent. Growth platform businesses include Genzyme developments – including rare disease products like Cerezyme and Fabrazyme, plus the late-stage multiple sclerosis products Aubagio (teriflunomide) and Lemtrada (alemtuzumab). Other growth platforms are diabetes, vaccines, consumer health care, animal health, new products and emerging markets.
26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more